Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2026-04-21 18:59:35 ET · period of report 2026-04-17 · accession 0001672659-26-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-21 18:59 | 2026-04-17 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $15.44 | +416 | 70.2K | +0.6% | +$6,423 |
| DT | 2026-04-21 18:59 | 2026-04-17 | MLYS | Rodman David Malcom | Chief Medical Off | S - Sale+OE | $31.33 | -416 | 69.8K | -0.6% | -$13.0K |
| DT | 2026-04-21 18:59 | 2026-04-17 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -416 | 4,584 | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-17 | M | A | 416 | $15.44 | 70,208 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| 2 | Common | Common Stock | 2026-04-17 | S | D | 416 | $31.33 | 69,792 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| 3 | Derivative | Stock Option | 2026-04-17 | M | D | 416 | $0.00 | 4,584 | D | $15.44 · — to 2033-03-17 | 416 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. (F2) The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |